Astria Therapeutics, Inc. (ATXS) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The prospects for Astria Therapeutics (ATXS) rely on the test results of its drug against angioedema, which is confirmed by the asset's market dynamics with the 0.00 indicator. Risks are linked to geopolitical logistics disruptions that are slowing down international studies. Currently, Astria Therapeutics (ATXS) is actively spending its accumulated capital on costly developments for treating rare immune pathologies, utilizing reserves to maintain an intensive R&D cycle.
astriatx.com - analytical breakdowns and key metrics (ATXS)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Astria Therapeutics|ATXS - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Astria Therapeutics, Inc.|ATXS - Company Cumulative Debt|Debts to Book Capitalization Astria Corp|ATXS - Company Long-Term Debts|Company Short-Term Debt Astria Therapeutics|Quick Liquidity Indicator astriatx.com
- business earnings and investment ratios data:
ATXS - Profit After Payment of Taxes|Expected Profit Astria Therapeutics|ATXS - Company Value to Net Income|Forward P/E Multiple Astria Therapeutics|ATXS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Astria Corp|ATXS - Operating profit EBITDA|Net earnings per share for the last 12 months Astria Therapeutics|ATXS - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months astriatx.com|ATXS - Net earnings per one share growth for the current year|Earnings growth forecast for next year Astria Therapeutics
Initial company analysis:Astria Pharma ATXS
Astria Therapeutics specializes in developing therapies for rare allergies with a lifelong consumption cycle. By analyzing the Enterprise Value to EBITDA multiple trend on GURU.Markets, an investor assesses the total business value relative to its operating profit before depreciation and interest. This ratio measures the payback period of assets, accounting for net debt and the tax burden. A stable metric confirms the ability of future excess profits to efficiently service capital obligations.
Competitors of Astria Therapeutics
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|DNTH - EV/EBITDA Multiple|Pharvaris N.V. (PHVS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABCL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TRML|PGEN (Precigen Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|Total Company Value to Operating Income Before Depreciation Ratio zenasbio.com (ZBIO)|Immunome - EV/EBITDA Multiple|GOSS - EV/EBITDA Multiple|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio PVLA|SVRA (savarapharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ENGN (enGene Bio)|rapt.com (RAPT) - Company Value to EBITDA|JBIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ACRS (aclaristx.com)|KYTX: EV/EBITDA Multiple|Tiziana Life Sciences Ltd. (TLSA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio, Inc|Ventyx Biosciences, Inc - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THTX|AVTX - Company Value to EBITDA|Eledon Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Agenus, Inc. AGEN|CLYM: Enterprise Value to EBITDA Ratio|zurabio.com - Enterprise Value to Operating Income Before Depreciation Ratio|ATYR: EV/EBITDA Multiple|ADAG - Total Company Value to Operating Income Before Depreciation Ratio|IMA (ImageneBio) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Shattuck Therapeutics (STTK)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Equillium, Inc. (EQ)|Total Company Value to Operating Income Before Depreciation Ratio connectbiopharm.com|EV/EBITDA Multiple IMUX (Immunic)|EV/EBITDA Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Enterprise Value to EBITDA Ratio|X4 Pharmaceuticals Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|ACET (adicetbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation CELU|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|barinthusbio.com (BRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kezar Life Sciences, Inc. (KZR)|SABS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|Business Value to Operating Income Before Depreciation ENLV|Q32 Bio Corp - EV/EBITDA Multiple|GOVX - EV/EBITDA Multiple|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|iBio Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Carisma Therapeutics Inc|Enterprise Value to EBITDA Ratio XTL Bio (XTLB)|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AIM|Aditxt Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRI Bio Corporation GRI|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to EBITDA Ratio SCNI (Scinai)|EV/EBITDA Multiple calcimedica.com (CALI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK: Enterprise Value to Operating Income Before Depreciation|HOOKIPA - EV/EBITDA Multiple|Company Value to EBITDA IGM Biosciences, Inc.|ITOS: EV/EBITDA Multiple|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|thirdharmonicbio.com (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
